inflammatory bowel disease
A graduate of the Y Combinator startup accelerator, the company combines shallow sequencing and data from a diverse population to predict treatment response.
Prometheus Biosciences Prices Upsized $190M IPO
The company is focused on developing and commercializing therapeutic and companion diagnostic products to treat inflammatory bowel disease.
KSL Biomedical to Commercialize PredictImmune IBD Test in North America
Under the deal, KSL will commercialize and facilitate orders of the PredictSURE IBD test throughout North America and will also process all samples through its laboratory, KSL Diagnostics.
Prometheus Biosciences, Takeda Pharmaceutical to Codevelop Targeted Therapies, CDx for IBD
Under the agreement, Prometheus will receive an upfront payment of an undisclosed amount and could receive up to $420 million in milestone payments.
After Spin Off From Prometheus, ProciseDx Targets POC Tests for Inflammatory, Autoimmune Conditions
Premium
The firm is conducting clinical trials in preparation for applying for FDA clearance to market its POC instrument and first assay in the first quarter of next year.